Deborah J. Wexler MD, MSc
Associate Professor of Medicine, Harvard Medical School; Chief, Diabetes Unit, Massachusetts General Hospital, Boston, MassachusettsDr. Deborah J. Wexler's research focuses on clinical effectiveness in type 2 diabetes. In addition, she is on the Editorial Board of Diabetes Care, and is a reviewer for multiple journals.
Disclosures
Dr. Wexler reports serving on Data Monitoring Committees for trials of oral semaglutide sponsored by Novo Nordisk.
Recent Contributions to PracticeUpdate:
- Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function
- 2019 Top Stories in Diabetes: The CREDENCE Trial
- Cannabis Use Is Associated With Increased Risk for Diabetic Ketoacidosis in Adults With Type 1 Diabetes
- Even Moderate Weight Loss After Diabetes Diagnosis Improves Long-Term Cardiovascular Risk
- Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
- ADA Scientific Sessions 2019: Recommendations From Dr. Deborah Wexler
- Morbidity and Mortality After Lifestyle Intervention for People With Impaired Glucose Tolerance
- 2018 Top Stories in Diabetes: Canagliflozin and Renal Outcomes in Type 2 Diabetes
- Levels of Adherence Needed to Achieve Significant Weight Loss
- Clinical Outcomes of an Integrated Primary–Secondary Model of Care for Complex Type 2 Diabetes